Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029

Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029

The biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029. Increasing need for cost and time reduction in the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive clinical trials. But there are some restraining factors in the market; the cost of biosimulation technologies is discouragingly high and thus, prohibitive to small companies and the academic community.

“Drug Discovery held the largest market share in the biosimulation market in 2023, by application.”

The biosimulation market is segmented based on application into drug discovery, drug development, disease modelling, manufacturing & supply chain management and other applications. The drug discovery segment held the largest market share in 2023, since it plays a vital role in accelerating and enriching early stages of pharmaceutical research. The tool created by biosimulation makes it possible for the researchers to simulate drug behavior at the molecular level, predict biological target interaction, even identify potential drug candidates before they reach the costly phases of preclinical and clinical trial stages. It reduces both the time and the cost incurred during the process of drug development.

“By deployment model, the cloud-based model segment is expected to register the fastest growth over the forecast period.”

By deployment model, the biosimulation market is divided into on-premises, cloud-based and hybrid model. The cloud-based segment is projected to be the fastest-growing segment over the forecast period. Cloud-based platforms are much more flexible and scalable and make very significant computational resources available at the point when they are needed to run complex biosimulations. This flexibility makes cloud models highly cost-effective, particularly for smaller biotech firms and academic institutions that would lack the infrastructure for high-performance computing.

“Asia Pacific is estimated to register the highest CAGR over the forecast period.”

The biosimulation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific biosimulation market is projected to register highest CAGR during the forecast period. The growth of this region is due to an aggressive build-out of the pharmaceutical and biotechnology industry in this region, especially in China, India, and South Korea, where large investments are committed to drug discovery and development. Markets in this region increasingly embrace sophisticated technology, such as biosimulation, to rationalize their R&D processes, reduce costs, and accelerate their time-to-market for new drugs.

Breakdown of supply-side primary interviews by company type, designation, and region:

By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)

By Designation: Managers (40%), Directors (35%), and Others (25%)

By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report:

Certara USA. (US)

Simulations Plus. (US)

Dassault Systèmes (France)

Schrödinger, Inc. (US)

Advanced Chemistry Development, Inc. (Canada)

Chemical Computing Group ULC. (Canada)

Rosa & Co. LLC. (US)

Genedata AG (US)

Physiomics Plc (United Kingdom)

In Silico Biosciences. (US)

Allucent. (US)

OpenEye, Cadence Molecular Sciences. (US)

Cellworks Group, Inc. (US)

VeriSIM Life. (US)

Netabolics SRL (Italy)

Charnwood Discovery (United Kingdom)

The MathWorks, Inc. (US)

ANSYS, Inc (US)

Instem Group of Companies (United Kingdom)

Insilico Medicine (US)

SCM – Software Chemistry & Materials (Netherlands)

BioSymetrics, Inc. (Canada)

Atomwise Inc. (US)

insitro. US)

Clinithink. (US)

Research Coverage:

This research report categorizes the biosimulation market by offerings (software and services), application (drug discovery, drug development, disease modelling, manufacturing & supply chain and other applications), therapeutic area (oncology, cardiovascular disease, neurological disorders, infectious disease, and others), revenue model (license-based model, subscription-based model, service-based model, and pay-per-use model), deployment model (on-premises model, cloud-based model, and hybrid model) end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutions, regulatory bodies and others), and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall biosimulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers: (increase in R&D investments in the pharmaceutical and biotechnology industries), restraints (lack of standardization), opportunities (use of biosimulation solution for pediatric drug development), and challenges (difficulty in matching the complexity of biological systems and processes) influencing the growth of the biosimulation market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the biosimulation market.

Market Development: Comprehensive information about lucrative markets – the report analyses the biosimulation market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the biosimulation market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Certara USA. (US), Simulations Plus. (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa & Co. LLC. (US), Genedata AG (US), etc. among others in biosimulation market.

Tables List

Table 1 Biosimulation Market: Role Of Companies In Ecosystem

Table 2 Biosimulation Market: Porter’s Five Forces

Table 3 North America: List Of Regulatory Bodies, Government Agencies, And Other Organizations

Table 4 Europe: List Of Regulatory Bodies, Government Agencies, And Other Organizations

Table 5 Asia Pacific: List Of Regulatory Bodies, Government Agencies, And Other Organizations

Table 6 Latin America: List Of Regulatory Bodies, Government Agencies, And Other Organizations

Table 7 Middle East & Africa: List Of Regulatory Bodies, Government Agencies, And Other Organizations

Table 8 Indicative Pricing Analysis Of Key Players, By Offering

Table 9 Biosimulation Market: Key Conferences And Events, 2024–2025

Table 10 Influence Of Stakeholders On Buying Process Of Top 3 End Users (%)

Table 11 Key Buying Criteria For Top 3 End Users

Table 12 Unmet Needs In Biosimulation Market

Table 13 End-user Expectations In Biosimulation Market

Table 14 Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 15 Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 16 Biosimulation Software Market, By Country, 2022–2029 (Usd Million)

Table 17 Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 18 Biosimulation Market For Standalone Modules, By Country,

2022–2029 (Usd Million)

Table 19 Biosimulation Market For Molecular Modeling & Simulation Software, By Country, 2022–2029 (Usd Million)

Table 20 Biosimulation Market For Pk/Pd Modeling & Simulation Software,

By Country, 2022–2029 (Usd Million)

Table 21 Biosimulation Market For Pbpk Modeling & Simulation Software,

By Country, 2022–2029 (Usd Million)

Table 22 Biosimulation Market For Toxicity Prediction Software, By Country, 2022–2029 (Usd Million)

Table 23 Biosimulation Market For Clinical Trial Simulation Software,

By Country, 2022–2029 (Usd Million)

Table 24 Biosimulation Market For Other Biosimulation Software, By Country, 2022–2029 (Usd Million)

Table 25 Biosimulation Market For Integrated Software Suites/Platforms,

By Country, 2022–2029 (Usd Million)

Table 26 Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 27 Biosimulation Services Market, By Country, 2022–2029 (Usd Million)

Table 28 Biosimulation Market For Consulting & Advisory Services, By Country, 2022–2029 (Usd Million)

Table 29 Biosimulation Market For Implementation, Training, And Support Services, By Country, 2022–2029 (Usd Million)

Table 30 Biosimulation Market For Data Analysis & Interpretation Services,

By Country, 2022–2029 (Usd Million)

Table 31 Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 32 Biosimulation Market For Drug Discovery Applications, By Type,

2022–2029 (Usd Million)

Table 33 Biosimulation Market For Drug Discovery Applications, By Country, 2022–2029 (Usd Million)

Table 34 Biosimulation Market For Target Identification & Validation,

By Country, 2022–2029 (Usd Million)

Table 35 Biosimulation Market For Lead Identification & Optimization,

By Country, 2022–2029 (Usd Million)

Table 36 Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 37 Biosimulation Market For Drug Development Applications, By Country, 2022–2029 (Usd Million)

Table 38 Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 39 Biosimulation Market For Preclinical Testing, By Country,

2022–2029 (Usd Million)

Table 40 Biosimulation Market For Pk/Pd, By Country, 2022–2029 (Usd Million)

Table 41 Biosimulation Market For Adme/Toxicology, By Country,

2022–2029 (Usd Million)

Table 42 Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 43 Biosimulation Market For Clinical Trials, By Country,

2022–2029 (Usd Million)

Table 44 Biosimulation Market For Phase I Clinical Trials, By Country,

2022–2029 (Usd Million)

Table 45 Biosimulation Market For Phase Ii Clinical Trials, By Country,

2022–2029 (Usd Million)

Table 46 Biosimulation Market For Phase Iii Clinical Trials, By Country,

2022–2029 (Usd Million)

Table 47 Biosimulation Market For Phase Iv/Post-marketing Surveillance,

By Country, 2022–2029 (Usd Million)

Table 48 Biosimulation Market For Disease Modeling Applications, By Country, 2022–2029 (Usd Million)

Table 49 Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 50 Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Country, 2022–2029 (Usd Million)

Table 51 Biosimulation Market For Production Planning & Optimization,

By Country, 2022–2029 (Usd Million)

Table 52 Biosimulation Market For Quality Control & Process Monitoring,

By Country, 2022–2029 (Usd Million)

Table 53 Biosimulation Market For Demand Forecasting & Inventory Management, By Country, 2022–2029 (Usd Million)

Table 54 Biosimulation Market For Risk Management & Contingency Planning, By Country, 2022–2029 (Usd Million)

Table 55 Biosimulation Market For Other Manufacturing & Supply Chain Management Applications, By Country, 2022–2029 (Usd Million)

Table 56 Biosimulation Market For Other Applications, By Country,

2022–2029 (Usd Million)

Table 57 Biosimulation Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 58 Biosimulation Market For Oncology, By Country,

2022–2029 (Usd Million)

Table 59 Biosimulation Market For Cardiovascular Diseases, By Country,

2022–2029 (Usd Million)

Table 60 Biosimulation Market For Neurological Disorders, By Country,

2022–2029 (Usd Million)

Table 61 Biosimulation Market For Infectious Diseases, By Country,

2022–2029 (Usd Million)

Table 62 Biosimulation Market For Other Therapeutic Areas, By Country,

2022–2029 (Usd Million)

Table 63 Biosimulation Market, By Revenue Model, 2022–2029 (Usd Million)

Table 64 Biosimulation Market For License-based Models, By Country,

2022–2029 (Usd Million)

Table 65 Biosimulation Market For Subscription-based Models, By Country, 2022–2029 (Usd Million)

Table 66 Biosimulation Market For Service-based Models, By Country,

2022–2029 (Usd Million)

Table 67 Biosimulation Market For Pay-per-use Models, By Country,

2022–2029 (Usd Million)

Table 68 Biosimulation Market, By Deployment Model, 2022–2029 (Usd Million)

Table 69 Biosimulation Market For On-premise Models, By Country,

2022–2029 (Usd Million)

Table 70 Biosimulation Market For Cloud-based Models, By Country,

2022–2029 (Usd Million)

Table 71 Biosimulation Market For Hybrid Models, By Country,

2022–2029 (Usd Million)

Table 72 Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 73 Biosimulation Market For Pharmaceutical & Biotechnology Companies, By Country, 2022–2029 (Usd Million)

Table 74 Biosimulation Market For Contract Research Organizations,

By Country, 2022–2029 (Usd Million)

Table 75 Biosimulation Market For Academic & Research Institutes, By Country, 2022–2029 (Usd Million)

Table 76 Biosimulation Market For Regulatory Bodies, By Country,

2022–2029 (Usd Million)

Table 77 Biosimulation Market For Other End Users, By Country,

2022–2029 (Usd Million)

Table 78 Biosimulation Market, By Region, 2022–2029 (Usd Million)

Table 79 North America: Biosimulation Market, By Country,

2022–2029 (Usd Million)

Table 80 North America: Biosimulation Market, By Offering,

2022–2029 (Usd Million)

Table 81 North America: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 82 North America: Biosimulation Market For Standalone Modules,

By Type, 2022–2029 (Usd Million)

Table 83 North America: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 84 North America: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 85 North America: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 86 North America: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 87 North America: Biosimulation Market For Preclinical Testing,

By Type, 2022–2029 (Usd Million)

Table 88 North America: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 89 North America: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 90 North America: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 91 North America: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 92 North America: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 93 North America: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 94 Us: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 95 Us: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 96 Us: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 97 Us: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 98 Us: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 99 Us: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 100 Us: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 101 Us: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 102 Us: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 103 Us: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 104 Us: Biosimulation Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 105 Us: Biosimulation Market, By Revenue Model, 2022–2029 (Usd Million)

Table 106 Us: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 107 Us: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 108 Canada: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 109 Canada: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 110 Canada: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 111 Canada: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 112 Canada: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 113 Canada: Biosimulation Market For Drug Discovery Applications,

By Type, 2022–2029 (Usd Million)

Table 114 Canada: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 115 Canada: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 116 Canada: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 117 Canada: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 118 Canada: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 119 Canada: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 120 Canada: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 121 Canada: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 122 Europe: Biosimulation Market, By Country, 2022–2029 (Usd Million)

Table 123 Europe: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 124 Europe: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 125 Europe: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 126 Europe: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 127 Europe: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 128 Europe: Biosimulation Market For Drug Discovery Applications,

By Type, 2022–2029 (Usd Million)

Table 129 Europe: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 130 Europe: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 131 Europe: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 132 Europe: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 133 Europe: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 134 Europe: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 135 Europe: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 136 Europe: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 137 Germany: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 138 Germany: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 139 Germany: Biosimulation Market For Standalone Modules, By Type, 2022–2029 (Usd Million)

Table 140 Germany: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 141 Germany: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 142 Germany: Biosimulation Market For Drug Discovery Applications,

By Type, 2022–2029 (Usd Million)

Table 143 Germany: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 144 Germany: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 145 Germany: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 146 Germany: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 147 Germany: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 148 Germany: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 149 Germany: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 150 Germany: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 151 Uk: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 152 Uk: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 153 Uk: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 154 Uk: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 155 Uk: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 156 Uk: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 157 Uk: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 158 Uk: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 159 Uk: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 160 Uk: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 161 Uk: Biosimulation Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 162 Uk: Biosimulation Market, By Revenue Model, 2022–2029 (Usd Million)

Table 163 Uk: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 164 Uk: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 165 France: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 166 France: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 167 France: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 168 France: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 169 France: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 170 France: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 171 France: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 172 France: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 173 France: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 174 France: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 175 France: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 176 France: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 177 France: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 178 France: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 179 Italy: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 180 Italy: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 181 Italy: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 182 Italy: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 183 Italy: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 184 Italy: Biosimulation Market For Drug Discovery Applications,

By Type, 2022–2029 (Usd Million)

Table 185 Italy: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 186 Italy: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 187 Italy: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 188 Italy: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 189 Italy: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 190 Italy: Biosimulation Market, By Revenue Model, 2022–2029 (Usd Million)

Table 191 Italy: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 192 Italy: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 193 Spain: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 194 Spain: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 195 Spain: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 196 Spain: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 197 Spain: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 198 Spain: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 199 Spain: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 200 Spain: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 201 Spain: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 202 Spain: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 203 Spain: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 204 Spain: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 205 Spain: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 206 Spain: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 207 Rest Of Europe: Biosimulation Market, By Offering,

2022–2029 (Usd Million)

Table 208 Rest Of Europe: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 209 Rest Of Europe: Biosimulation Market For Standalone Modules,

By Type, 2022–2029 (Usd Million)

Table 210 Rest Of Europe: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 211 Rest Of Europe: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 212 Rest Of Europe: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 213 Rest Of Europe: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 214 Rest Of Europe: Biosimulation Market For Preclinical Testing, By Type, 2022–2029 (Usd Million)

Table 215 Rest Of Europe: Biosimulation Market For Clinical Trials, By Type, 2022–2029 (Usd Million)

Table 216 Rest Of Europe: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 217 Rest Of Europe: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 218 Rest Of Europe: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 219 Rest Of Europe: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 220 Rest Of Europe: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 221 Asia Pacific: Biosimulation Market, By Country, 2022–2029 (Usd Million)

Table 222 Asia Pacific: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 223 Asia Pacific: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 224 Asia Pacific: Biosimulation Market For Standalone Modules, By Type, 2022–2029 (Usd Million)

Table 225 Asia Pacific: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 226 Asia Pacific: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 227 Asia Pacific: Biosimulation Market For Drug Discovery Applications,

By Type, 2022–2029 (Usd Million)

Table 228 Asia Pacific: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 229 Asia Pacific: Biosimulation Market For Preclinical Testing, By Type, 2022–2029 (Usd Million)

Table 230 Asia Pacific: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 231 Asia Pacific: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 232 Asia Pacific: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 233 Asia Pacific: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 234 Asia Pacific: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 235 Asia Pacific: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 236 China: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 237 China: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 238 China: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 239 China: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 240 China: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 241 China: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 242 China: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 243 China: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 244 China: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 245 China: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 246 China: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 247 China: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 248 China: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 249 China: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 250 India: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 251 India: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 252 India: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 253 India: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 254 India: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 255 India: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 256 India: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 257 India: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 258 India: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 259 India: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 260 India: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 261 India: Biosimulation Market, By Revenue Model, 2022–2029 (Usd Million)

Table 262 India: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 263 India: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 264 Japan: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 265 Japan: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 266 Japan: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 267 Japan: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 268 Japan: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 269 Japan: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 270 Japan: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 271 Japan: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 272 Japan: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 273 Japan: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 274 Japan: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 275 Japan: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 276 Japan: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 277 Japan: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 278 Rest Of Asia Pacific: Biosimulation Market, By Offering,

2022–2029 (Usd Million)

Table 279 Rest Of Asia Pacific: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 280 Rest Of Asia Pacific: Biosimulation Market For Standalone Modules,

By Type, 2022–2029 (Usd Million)

Table 281 Rest Of Asia Pacific: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 282 Rest Of Asia Pacific: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 283 Rest Of Asia Pacific: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 284 Rest Of Asia Pacific: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 285 Rest Of Asia Pacific: Biosimulation Market For Preclinical Testing,

By Type, 2022–2029 (Usd Million)

Table 286 Rest Of Asia Pacific: Biosimulation Market For Clinical Trials, By Type, 2022–2029 (Usd Million)

Table 287 Rest Of Asia Pacific: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 288 Rest Of Asia Pacific: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 289 Rest Of Asia Pacific: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 290 Rest Of Asia Pacific: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 291 Rest Of Asia Pacific: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 292 Latin America: Biosimulation Market, By Country,

2022–2029 (Usd Million)

Table 293 Latin America: Biosimulation Market, By Offering,

2022–2029 (Usd Million)

Table 294 Latin America: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 295 Latin America: Biosimulation Market For Standalone Modules, By Type, 2022–2029 (Usd Million)

Table 296 Latin America: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 297 Latin America: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 298 Latin America: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 299 Latin America: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 300 Latin America: Biosimulation Market For Preclinical Testing,

By Type, 2022–2029 (Usd Million)

Table 301 Latin America: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 302 Latin America: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 303 Latin America: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 304 Latin America: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 305 Latin America: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 306 Latin America: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 307 Brazil: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 308 Brazil: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 309 Brazil: Biosimulation Market For Standalone Modules, By Type,

2022–2029 (Usd Million)

Table 310 Brazil: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 311 Brazil: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 312 Brazil: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 313 Brazil: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 314 Brazil: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 315 Brazil: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 316 Brazil: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 317 Brazil: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 318 Brazil: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 319 Brazil: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 320 Brazil: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 321 Mexico: Biosimulation Market, By Offering, 2022–2029 (Usd Million)

Table 322 Mexico: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 323 Mexico: Biosimulation Market For Standalone Modules, By Type, 2022–2029 (Usd Million)

Table 324 Mexico: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 325 Mexico: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 326 Mexico: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 327 Mexico: Biosimulation Market For Drug Development Applications,

By Type, 2022–2029 (Usd Million)

Table 328 Mexico: Biosimulation Market For Preclinical Testing, By Type,

2022–2029 (Usd Million)

Table 329 Mexico: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 330 Mexico: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 331 Mexico: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 332 Mexico: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 333 Mexico: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 334 Mexico: Biosimulation Market, By End User, 2022–2029 (Usd Million)

Table 335 Rest Of Latin America: Biosimulation Market, By Offering,

2022–2029 (Usd Million)

Table 336 Rest Of Latin America: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 337 Rest Of Latin America: Biosimulation Market For Standalone Modules, By Type, 2022–2029 (Usd Million)

Table 338 Rest Of Latin America: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 339 Rest Of Latin America: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 340 Rest Of Latin America: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 341 Rest Of Latin America: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 342 Rest Of Latin America: Biosimulation Market For Preclinical Testing,

By Type, 2022–2029 (Usd Million)

Table 343 Rest Of Latin America: Biosimulation Market For Clinical Trials, By Type, 2022–2029 (Usd Million)

Table 344 Rest Of Latin America: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type,

2022–2029 (Usd Million)

Table 345 Rest Of Latin America: Biosimulation Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 346 Rest Of Latin America: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 347 Rest Of Latin America: Biosimulation Market, By Deployment Model, 2022–2029 (Usd Million)

Table 348 Rest Of Latin America: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 349 Middle East & Africa: Biosimulation Market, By Country,

2022–2029 (Usd Million)

Table 350 Middle East & Africa: Biosimulation Market, By Offering,

2022–2029 (Usd Million)

Table 351 Middle East & Africa: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 352 Middle East & Africa: Biosimulation Market For Standalone Modules, By Type, 2022–2029 (Usd Million)

Table 353 Middle East & Africa: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 354 Middle East & Africa: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 355 Middle East & Africa: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 356 Middle East & Africa: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 357 Middle East & Africa: Biosimulation Market For Preclinical Testing,

By Type, 2022–2029 (Usd Million)

Table 358 Middle East & Africa: Biosimulation Market For Clinical Trials, By Type, 2022–2029 (Usd Million)

Table 359 Middle East & Africa: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type,

2022–2029 (Usd Million)

Table 360 Middle East & Africa: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 361 Middle East & Africa: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 362 Middle East & Africa: Biosimulation Market, By Deployment Model, 2022–2029 (Usd Million)

Table 363 Middle East & Africa: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 364 Gcc Countries: Biosimulation Market, By Offering,

2022–2029 (Usd Million)

Table 365 Gcc Countries: Biosimulation Software Market, By Type,

2022–2029 (Usd Million)

Table 366 Gcc Countries: Biosimulation Market For Standalone Modules, By Type, 2022–2029 (Usd Million)

Table 367 Gcc Countries: Biosimulation Services Market, By Type,

2022–2029 (Usd Million)

Table 368 Gcc Countries: Biosimulation Market, By Application,

2022–2029 (Usd Million)

Table 369 Gcc Countries: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 370 Gcc Countries: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 371 Gcc Countries: Biosimulation Market For Preclinical Testing, By Type, 2022–2029 (Usd Million)

Table 372 Gcc Countries: Biosimulation Market For Clinical Trials, By Type,

2022–2029 (Usd Million)

Table 373 Gcc Countries: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 374 Gcc Countries: Biosimulation Market, By Therapeutic Area,

2022–2029 (Usd Million)

Table 375 Gcc Countries: Biosimulation Market, By Revenue Model,

2022–2029 (Usd Million)

Table 376 Gcc Countries: Biosimulation Market, By Deployment Model,

2022–2029 (Usd Million)

Table 377 Gcc Countries: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 378 Rest Of Middle East & Africa: Biosimulation Market, By Offering,

2022–2029 (Usd Million)

Table 379 Rest Of Middle East & Africa: Biosimulation Software Market, By Type, 2022–2029 (Usd Million)

Table 380 Rest Of Middle East & Africa: Biosimulation Market For Standalone Modules, By Type, 2022–2029 (Usd Million)

Table 381 Rest Of Middle East & Africa: Biosimulation Services Market, By Type, 2022–2029 (Usd Million)

Table 382 Rest Of Middle East & Africa: Biosimulation Market, By Application, 2022–2029 (Usd Million)

Table 383 Rest Of Middle East & Africa: Biosimulation Market For Drug Discovery Applications, By Type, 2022–2029 (Usd Million)

Table 384 Rest Of Middle East & Africa: Biosimulation Market For Drug Development Applications, By Type, 2022–2029 (Usd Million)

Table 385 Rest Of Middle East & Africa: Biosimulation Market For Preclinical Testing, By Type, 2022–2029 (Usd Million)

Table 386 Rest Of Middle East & Africa: Biosimulation Market For Clinical Trials, By Type, 2022–2029 (Usd Million)

Table 387 Rest Of Middle East & Africa: Biosimulation Market For Manufacturing & Supply Chain Management Applications, By Type, 2022–2029 (Usd Million)

Table 388 Rest Of Middle East & Africa: Biosimulation Market, By Therapeutic Area, 2022–2029 (Usd Million)

Table 389 Rest Of Middle East & Africa: Biosimulation Market, By Revenue Model, 2022–2029 (Usd Million)

Table 390 Rest Of Middle East & Africa North America: Biosimulation Market,

By Deployment Model, 2022–2029 (Usd Million)

Table 391 Rest Of Middle East & Africa: Biosimulation Market, By End User,

2022–2029 (Usd Million)

Table 392 Overview Of Strategies Adopted By Key Players In Biosimulation Market

Table 393 Biosimulation Market: Degree Of Competition

Table 394 Biosimulation Market: Offering Footprint

Table 395 Biosimulation Market: Application Footprint

Table 396 Biosimulation Market: End-user Footprint

Table 397 Biosimulation Market: Region Footprint

Table 398 Biosimulation Market: Detailed List Of Key Start-ups/Smes

Table 399 Biosimulation Market: Competitive Benchmarking Of Key Emerging Players/Startups

Table 400 Biosimulation Market: Product Launches & Enhancements, January 2021–october 2024

Table 401 Biosimulation Market: Deals, January 2021–october 2024

Table 402 Biosimulation Market: Expansions, January 2021–october 2024

Table 403 Biosimulation Market: Other Developments,

January 2021–october 2024

Table 404 Certara, Usa: Company Overview

Table 405 Certara, Usa: Products & Services Offered

Table 406 Certara, Usa: Product Launches & Enhancements, January 2021−october 2024

Table 407 Certara, Usa: Deals, January 2021−october 2024

Table 408 Dassault Systèmes: Company Overview

Table 409 Dassault Systèmes: Products & Services Offered

Table 410 Dassault Systèmes: Deals, January 2021−june 2024

Table 411 Schrödinger, Inc.: Company Overview

Table 412 Schrödinger, Inc.: Products & Services Offered

Table 413 Schrödinger, Inc.: Deals, January 2021−october 2024

Table 414 Simulations Plus: Company Overview

Table 415 Simulations Plus: Products & Services Offered

Table 416 Simulations Plus: Product Launches & Enhancements, January 2021−october 2024

Table 417 Simulations Plus: Deals, January 2021−october 2024

Table 418 Simulations Plus: Other Developments, January 2021–october 2024

Table 419 Advanced Chemistry Development, Inc.: Company Overview

Table 420 Advanced Chemistry Development, Inc.: Products & Services Offered

Table 421 Advanced Chemistry Development, Inc.: Product Launches & Enhancements, January 2021−october 2024

Table 422 Advanced Chemistry Development, Inc.: Deals,

January 2021−october 2024

Table 423 Chemical Computing Group Ulc: Company Overview

Table 424 Chemical Computing Group Ulc: Products & Services Offered

Table 425 Chemical Computing Group Ulc: Deals, January 2021−october 2024

Table 426 Rosa & Co. Llc: Company Overview

Table 427 Rosa & Co. Llc: Products & Services Offered

Table 428 Genedata Ag (A Danaher Company): Company Overview

Table 429 Genedata Ag (A Danaher Company): Products & Services Offered

Table 430 Genedata Ag (A Danaher Company): Product Launches & Enhancements, January 2021−october 2024

Table 431 Genedata Ag (A Danaher Company): Deals, January 2021−october 2024

Table 432 Physiomics Plc: Company Overview

Table 433 Physiomics Plc: Products & Services Offered

Table 434 Physiomics Plc: Deals, January 2021−october 2024

Table 435 In Silico Biosciences: Company Overview

Table 436 In Silico Biosciences: Products & Services Offered

Table 437 Allucent: Company Overview

Table 438 Allucent: Products & Services Offered

Table 439 Allucent: Deals, January 2021−october 2024

Table 440 Allucent: Expansions, January 2021–october 2024

Table 441 Openeye, Cadence Molecular Sciences: Company Overview

Table 442 Openeye, Cadence Molecular Sciences: Products & Services Offered

Table 443 Openeye, Cadence Molecular Sciences: Product Enhancements, January 2021−october 2024

Table 444 Openeye, Cadence Molecular Sciences: Deals,

January 2021−october 2024

Table 445 Openeye, Cadence Molecular Sciences: Expansions,

January 2021–october 2024

Table 446 Cellworks Group, Inc.: Company Overview

Table 447 Cellworks Group, Inc.: Products & Services Offered

Table 448 Cellworks Group, Inc.: Expansions, January 2021–october 2024

Table 449 Verisim Life: Company Overview

Table 450 Verisim Life: Products & Services Offered

Table 451 Verisim Life: Deals, January 2021−october 2024

Table 452 Verisim Life: Other Developments, January 2021–october 2024

Table 453 Netabolics: Company Overview

Table 454 Netabolics: Products & Services Offered

Table 455 Charnwood Discovery: Company Overview

Table 456 Charnwood Discovery: Products & Services Offered

Table 457 Charnwood Discovery: Deals, January 2021−october 2024

Table 458 The Mathworks, Inc.: Company Overview

Table 459 The Mathworks, Inc.: Products & Services Offered

Table 460 The Mathworks, Inc.: Product Enhancements,

January 2021−october 2024

Table 461 Ansys, Inc.: Company Overview

Table 462 Ansys, Inc.: Products & Services Offered

Figures List

Figure 1 Biosimulation Market Segmentation & Regional Scope

Figure 2 Research Design

Figure 3 Primary Sources

Figure 4 Breakdown Of Primary Interviews (Demand Side): By Company Type, Designation, And Region

Figure 5 Market Size Estimation: Revenue Share Analysis

Figure 6 Top-down Approach

Figure 7 Cagr Projections, 2024–2029

Figure 8 Cagr Projections: Supply-side Analysis

Figure 9 Data Triangulation

Figure 10 Biosimulation Market, By Offering, 2024 Vs. 2029 (Usd Million)

Figure 11 Biosimulation Market, By Application, 2024 Vs. 2029 (Usd Million)

Figure 12 Biosimulation Market, By Therapeutic Area, 2024 Vs. 2029 (Usd Million)

Figure 13 Biosimulation Market, By Revenue Model, 2024 Vs. 2029 (Usd Million)

Figure 14 Biosimulation Market, By Deployment Model,

2024 Vs. 2029 (Usd Million)

Figure 15 Biosimulation Market, By End User, 2024 Vs. 2029 (Usd Million)

Figure 16 Geographic Snapshot Of Biosimulation Market

Figure 17 Increasing R&D Expenditure On Drug Discovery & Development By Pharmaceutical & Biotechnology Companies To Drive Market

Figure 18 China Dominated Market In Asia Pacific In 2023

Figure 19 India To Register Highest Growth Rate During Forecast Period

Figure 20 North America To Dominate Biosimulation Market During Forecast Period

Figure 21 Emerging Economies To Register Higher Growth Rates During Forecast Period

Figure 22 Biosimulation Market: Drivers, Restraints, Opportunities, And Challenges

Figure 23 Biosimulation Market: Ecosystem Analysis

Figure 24 Biosimulation Market: Value Chain Analysis

Figure 25 Biosimulation Market: Porter’s Five Forces Analysis

Figure 26 Patent Publication Trends In Biosimulation Market, 2015–2024

Figure 27 Biosimulation Market: Patent Analysis, January 2015–september 2024

Figure 28 Indicative Pricing Analysis For Biosimulation Software

Figure 29 Influence Of Stakeholders On Buying Process Of Top 3 End Users

Figure 30 Key Buying Criteria For Top 3 End Users

Figure 31 Trends & Disruptions Impacting Customers’ Businesses

Figure 32 Biosimulation Market: Investment & Funding Scenario

Figure 33 Market Potential Of Ai/Generative Ai On Biosimulation

Figure 34 Impact Of Ai/Gen Ai On Interconnected And Adjacent Ecosystems

Figure 35 North America: Biosimulation Market Snapshot

Figure 36 Asia Pacific: Biosimulation Market Snapshot

Figure 37 Revenue Analysis Of Key Players In Biosimulation Market,

2019–2023 (Usd Billion)

Figure 38 Biosimulation Market: Market Share Analysis (2023)

Figure 39 Ranking Of Key Players In Biosimulation Market, 2023

Figure 40 Biosimulation Market: Company Evaluation Matrix (Key Players), 2023

Figure 41 Biosimulation Market: Company Footprint

Figure 42 Biosimulation Market: Company Evaluation Matrix

(Start-ups/Smes), 2023

Figure 43 Ev/Ebitda Of Key Vendors

Figure 44 Year-to-date (Ytd) Price Total Return And 5-year Stock Beta Of Biosimulation Vendors

Figure 45 Biosimulation Market: Brand/Product Comparative Analysis

Figure 46 Certara, Usa: Company Snapshot (2023)

Figure 47 Dassault Systèmes: Company Snapshot (2023)

Figure 48 Schrödinger, Inc.: Company Snapshot (2023)

Figure 49 Simulations Plus: Company Snapshot (2023)

Figure 50 Genedata Ag (A Danaher Company): Company Snapshot (2023)

Figure 51 Physiomics Plc: Company Snapshot (2023)

Figure 52 Openeye, Cadence Molecular Sciences: Company Snapshot (2023)

Figure 53 Ansys, Inc.: Company Snapshot (2023)